Citryll is a high-potential biotechnology company (Series B, €85M raised in Dec 2024) developing novel NET-targeting therapeutics (CIT-013) for autoimmune diseases. While the project entity possesses exceptional real-world utility, technical innovation, and verifiable financial traction, the submission itself contained significantly inaccurate claims (e.g., 'most people have used my product', audience reach 'everyone') which severely impacted the Response Quality and Audience Reach scores. The evaluation rewards the verifiable external success of the company while penalizing the poor quality of the submission data.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline